Eli Lilly axes next-generation, resistance-busting RET inhibitor

Eli Lilly has axed its next-generation RET inhibitor. The Big Pharma pushed the candidate, LOXO-260, into the clinic to overcome acquired resistance to existing drugs such as its own Retevmo but has now pulled it from the pipeline before clearing phase 1.